Table 3.

Sensitivity analyses after excluding metformin irregular users who had two consecutive prescriptions spanning more than four months.

Tuberculosis Infection/Metformin Exposure	n	N	HR	95% CI	p Value
Any tuberculosis infection
Never users	360	15,799	1.000
Ever users	496	50,195	0.438	(0.382–0.501)	<0.0001
Tertiles of cumulative duration of metformin therapy (months)
Never users	360	15,799	1.000
<27.10	217	16,349	0.889	(0.748–1.055)	0.1781
27.10–58.27	167	13,683	0.523	(0.435–0.628)	<0.0001
>58.27	112	20,163	0.190	(0.153–0.235)	<0.0001
Tertiles of cumulative dose of metformin therapy (mg)
Never users	360	15,799	1.000
<817,000	218	16,919	0.847	(0.713–1.005)	0.0572
817,000–2,047,180	151	14,180	0.443	(0.366–0.535)	<0.0001
>2,047,180	127	19,096	0.230	(0.188–0.282)	<0.0001
Pulmonary tuberculosis infection
Never users	324	15,799	1.000
Ever users	439	50,195	0.431	(0.373–0.497)	<0.0001
Tertiles of cumulative duration of metformin therapy (months)
Never users	324	15,799	1.000
<27.10	190	16,349	0.852	(0.710–1.023)	0.0853
27.10–58.27	149	13,683	0.517	(0.426–0.629)	<0.0001
>58.27	100	20,163	0.189	(0.151–0.237)	<0.0001
Tertiles of cumulative dose of metformin therapy (mg)
Never users	324	15,799	1.000
<817,000	191	16,919	0.813	(0.678–0.976)	0.0262
817,000–2,047,180	135	14,180	0.440	(0.360–0.537)	<0.0001
>2,047,180	113	19,096	0.228	(0.184–0.283)	<0.0001

n: incident case number of tuberculosis infection, N: case number followed. HR: hazard ratio (propensity score weighted), CI: confidence interval.